Wechselwirkungen · Zalasta
Zalasta 2.5 mg tablets Zalasta 5 mg tablets Zalasta 7.5 mg tablets Zalasta 10 mg tablets Zalasta 15 mg tablets Zalasta 20 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-118112 · Präparat HOS-094761
Inhibition of CYP1A2 Fluvoxamine, a specific CYP 1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine. The mean increase in olanzapine Cmax following fluvoxamine was 54% in female non-smokers and 77% in male smokers. The mean increase in olanzapine AUC was 52% and 108% respectively. A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin. A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP 1A2 is initiated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ciprofloxacin (HOS-085177) fluvoxamine (HOS-085908)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-03-08T12:05:00Z · SHA-256 3a142a418d0e0a235e959dcbf43b8874bc768eb3299e63f7c0947414404ebe0b · Passage b3cf8df3a44c6f85e65efb4008082fc5536a7ce3fe3d8164ccd064c0eb56d063 · Zeichen 658–1236 im Abschnitt